Regulation of Apolipoprotein Metabolism: Increased Hepatic Secretion of Very-Low-Density-Lipoprotein Apolipoprotein B100 in Non-Insulin Dependent Diabetes and Heterozygous Familial Hypercholesterolaemia

1994 ◽  
Vol 87 (s31) ◽  
pp. 12P-12P
Author(s):  
MH Cummings ◽  
GF Watts ◽  
AM Umploby ◽  
PJ Lumb ◽  
J Kelly ◽  
...  
Keyword(s):  
Familial Hypercholesterolaemia ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Insulin Dependent Diabetes ◽  
Very Low Density Lipoprotein ◽  
Low Density ◽  
Apolipoprotein B100 ◽  
Insulin Dependent ◽  
Heterozygous Familial Hypercholesterolaemia

Integrated study of low density lipoprotein metabolism and very low density lipoprotein metabolism in non-insulin-dependent diabetes

Metabolism ◽  
1987 ◽  
Vol 36 (9) ◽  
pp. 870-877 ◽  
Author(s):  
Barbara V. Howard ◽  
William G.H. Abbott ◽  
William F. Beltz ◽  
Ingeborg T. Harper ◽  
Rose M. Fields ◽  
...  
Keyword(s):  
Low Density Lipoprotein ◽  
Lipoprotein Metabolism ◽  
Density Lipoprotein ◽  
Insulin Dependent Diabetes ◽  
Very Low Density Lipoprotein ◽  
Low Density ◽  
Insulin Dependent ◽  
Integrated Study

Treatment of familial hypercholesterolaemia in children and adolescents in the last three decades

2013 ◽  
Vol 24 (3) ◽  
pp. 437-441 ◽  
Author(s):  
Avishay Elis ◽  
Rong Zhou ◽  
Evan A. Stein
Keyword(s):  
Children And Adolescents ◽  
Familial Hypercholesterolaemia ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Lipoprotein Cholesterol ◽  
Low Density ◽  
Low Density Lipoprotein Cholesterol ◽  
Cholesterol Levels ◽  
Heterozygous Familial Hypercholesterolaemia

AbstractBackground:This study evaluated the effectiveness of long-term intensive lipid-lowering therapy in children and adolescents with familial hypercholesterolaemia.Methods:The charts of 89 children and adolescents with heterozygous familial hypercholesterolaemia among ∼1000 patients treated from 1974 to 2008 were reviewed. Familial hypercholesterolaemia was defined as low-density lipoprotein cholesterol level >90th percentile in individuals with a history of familial hypercholesterolaemia.Results:Of the 89 patients, 51% were male; the mean age at diagnosis was 8 ± 4 years, and the mean follow-up was 13 ± 8 years. Baseline and most recent low-density lipoprotein cholesterol levels (mg/dl) under treatment were 250 ± 50 and 142 ± 49, respectively, reduced 43% from baseline (p < 0.0001). At the most recent visit, 39 patients received statin monotherapy, mainly atorvastatin or rosuvastatin, and 50 (56%) patients received combination therapy, mainly vytorin or rosuvastain/ezetimibe, 15 patients were >30 years of age, and none developed symptomatic cardiovascular disease or needed revascularisation.Conclusions:Long-term statin-based therapy can reduce low-density lipoprotein cholesterol levels in most children and adolescents with heterozygous familial hypercholesterolaemia and decrease cardiovascular risk significantly.

Sign in / Sign up

Export Citation Format

Share Document